Holen Sie sich die Stockscreener-App
0.3699
2.75%
0.0099
Handel nachbörslich:
.37
0.000100
+0.03%
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
Can IGC Pharma Inc. stock recover from recent declinePortfolio Growth Summary & Growth-Oriented Investment Plans - Newser
Risk vs reward if holding onto IGC Pharma Inc.2025 Bull vs Bear & Smart Money Movement Alerts - Newser
Key metrics from IGC Pharma Inc.’s quarterly dataJuly 2025 Final Week & Pattern Based Trade Signal System - Newser
Trend analysis for IGC Pharma Inc. this weekJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
IGC Pharma highlights preclinical data on IGC-M3 - MSN
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Sector ETF performance correlation with IGC Pharma Inc.Quarterly Portfolio Report & Smart Money Movement Alerts - Newser
Can IGC Pharma Inc. recover in the next quarterTrade Risk Summary & Long-Term Safe Investment Ideas - Newser
Understanding IGC Pharma Inc.’s price movement2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - Newser
What makes IGC Pharma Inc. stock price move sharplyCapital Secure Pattern Signal Analysis Sheet - Newser
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - GlobeNewswire
Can IGC Pharma Inc. withstand a market correctionMulti-Timeframe Confluence Picks - thegnnews.com
Long term hold vs stop loss in IGC Pharma Inc.High Conviction Screener with Trend Matching - Newser
Chart overlay techniques for tracking IGC Pharma Inc.Free Smart Money Tracking Signal Generator - Newser
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - SINA HONG KONG LIMITED
Can IGC Pharma Inc. expand its profit marginsRocket Picks with Low Risk - newsyoung.net
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
IGC Pharma's IGC-M3 Demonstrates Promising Preclinical Data in Alzheimer's Disease - AInvest
New Alzheimer's Drug IGC-M3 Targets Multiple Disease Pathways with 90% Efficacy in Preclinical Tests - Stock Titan
Can IGC Pharma Inc. weather a recessionFree Trend Analysis Tool - metrotimes.co.kr
What's driving IGC's earnings surprises recently? - AInvest
Can IGC maintain its Q2 2025 earnings momentum? - AInvest
Using Ichimoku Cloud for IGC Pharma Inc. technicalsFree AI Screening for Swing Trade Picks - Newser
Is IGC Pharma Inc. stock bottoming outTrade Safety Report with Pattern Insights - Newser
What hedge funds are buying IGC Pharma Inc.Positive Free Cash Flow Watch - classian.co.kr
Evaluating IGC Pharma Inc. with trendline analysisFree AI Driven Buy Alert Trade Blueprint - Newser
Key resistance and support levels for IGC Pharma Inc.Capital Protection Strategy With Risk Analysis - Newser
Can a trend reversal in IGC Pharma Inc. lead to recoveryPrice Action Summary and Entry Strategy Guide - Newser
Using economic indicators to assess IGC Pharma Inc. potentialFree Reliable Chart-Based Trade Entries - Newser
IGC Pharma Reports Promising In Vitro Efficacy of IGC-M3 Against Alzheimer's Disease - AInvest
IGC Pharma's IGC-M3 Shows Promise in Alzheimer's Treatment: Targets Key Drivers of Disease Progression - AInvest
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer'sTargeting key Drivers of Disease Progression - ACCESS Newswire
Breakthrough: New Alzheimer's Drug Candidate Targets 4 Disease PathwaysIGC-M3 Shows Early Promise - Stock Titan
Azul secures US$650m backstop to fund Chapter 11 equity raise | IGC SEC FilingForm PRE 14A - Stock Titan
Should I hold or sell IGC Pharma Inc. stock in 2025Capitalize on momentum-driven investment opportunities - Jammu Links News
Does IGC Pharma Inc. stock perform well during market downturnsGain insights from top financial experts - Jammu Links News
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):